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1  | INTRODUC TION
Fluid bolus therapy is a widely used intervention in the treatment of 
critically ill patients.1,2 Fluid boluses are typically administered in the 
optimization phase of fluid resuscitation aiming to optimize and main-
tain adequate organ perfusion by increasing stroke volume.3 After hy-
potension, oliguria (urine output less than 0.5 mL/kg/h) was the most 
common trigger to administer a fluid bolus.2 Albeit oliguria is often 
seen as a manifestation of inadequate organ perfusion that can be due 
to hypovolemia, distributive shock, or depressed cardiac function, it 
can also be a manifestation of early acute kidney injury (AKI).4
Regrettably, the response to fluid bolus is currently poorly docu-
mented in clinical practice.2 A recent systematic review among septic 
patients found no previous randomized trials comparing the efficacy 
of fluid bolus therapy to alternative interventions.1 Moreover, few 
observational studies have reported data regarding urine output in 
response to fluid bolus therapy, and these data suggest no clinically 
meaningful response.1 A retrospective analysis among patients with 
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Background: Oliguria is a frequent trigger for administering a fluid bolus, but the ef-
fect of fluid bolus in improving urine output is inadequately demonstrated. Here, we 
summarize the protocol and detailed statistical analysis plan of the randomized, con-
trolled RESPONSE trial comparing follow-up as the experimental group and a 500 mL 
crystalloid fluid bolus as the control group for oliguria in critically ill oliguric patients.
Methods: Our trial is an investigator-initiated, randomized, controlled, pilot trial 
conducted in three ICUs in two centers. We aim to randomize 1:1 altogether 130 
hemodynamically stable oliguric patients either to a 2-hour follow-up without inter-
ventions or to receive a crystalloid bolus of 500 mL over 30 minutes. The primary 
outcome is the change in individual urine output during the 2-hour period compared 
to 2 hours preceding randomization. Doubling of the urine output is considered clini-
cally significant. Additionally, we record the duration of oliguria, physiological and 
biochemical variables, adverse events, and the incidences of acute kidney injury and 
renal replacement therapy.
Conclusions: Oliguria is a frequent trigger for potentially harmful fluid loading. 
Therefore, the RESPONSE trial will give information of the potential effect of fluid 
bolus on oliguria in critically ill patients.
Trial registration: clinical.trials.gov, NCT02860572.
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acute respiratory distress syndrome in a randomized trial comparing 
conservative vs liberal fluid management found that urine output did 
not significantly increase within 4 hours after a fluid bolus.5 A small 
observational study among septic shock patients did not find fluid bo-
luses to increase urine output6 whereas another study reported urine 
output to increase approximately by 50% both among patients with 
oliguria and AKI after a large fluid bolus (median volume 1224 mL crys-
talloid or colloid).7 Additionally, improvement in systemic hemody-
namics after fluid bolus has been found to correlate poorly with renal 
hemodynamics,7-10 further complicating the assessment of potential 
benefits of fluid bolus in terms of reversing oliguria. Moreover, the 
effect of fluid bolus on cardiovascular variables is short-lived among 
patients in shock11,12 suggesting that fluid boluses in the optimization 
phase of shock are unlikely to improve patient-centered outcomes.
A typically administered fluid bolus is 500 mL of crystalloid 
given over 30 minutes,2 and fluid boluses may constitute a marked 
proportion, up to 50%, of the fluid amount administered daily.6 A 
growing body of evidence suggests a poor renal response to fluid 
bolus,5,6 which particularly among oliguric patients translates to an 
increased risk of fluid accumulation. Moreover, a growing body of 
evidence shows association of fluid accumulation with increased risk 
of mortality.13-16
Therefore, in oliguric critically ill patients, clinical equipoise 
exists in conducting a randomized trial that aims to compare a fol-
low-up approach without any fluid bolus to standard therapy with 
fluid bolus (500 mL of crystalloid administered over 30 minutes). We 
hypothesize that the incidence of doubling of urine output will not 
differ between the groups to a clinically significant level defined as 
at least a 20% absolute increase in the number of responders.
2  | METHODS
2.1 | Trial design and setting
The RESPONSE trial is an investigator-initiated, open, randomized, 
controlled, pilot study conducted in two Finnish centers; two inten-
sive care units (ICUs) in Helsinki University Hospital (Helsinki) and in 
the ICU of Central Finland Central Hospital (Jyväskylä).
2.2 | Trial registration
The RESPONSE trial was registered in the clinicaltrials.gov registry 
(identifier NCT02860572) on 9 August 2016.
2.3 | Trial conduct
The study protocol has been prepared in accordance with the 
Standard Protocol Items: Recommendations for Interventional Trials 
(SPIRIT) guidelines.17 The study will be conducted according to the 
Declaration of Helsinki and its later amendments and according the 
Good Clinical Practice guidelines.
2.4 | Randomization
Eligible patients will be randomized 1:1 within 1 hour of full eligibil-
ity using computer-based algorithm created by an independent stat-
istician and web-based allocation concealment for randomization. 
Randomization is stratified according to the presence/absence of 
AKI (defined by KDIGO criteria4) and sepsis (according to the Sepsis 
definition18). Permutated blocks of varying size (4, 6, or 8) are used.
2.5 | Blinding
Due to the nature of the study, blinding of the ICU personnel is not 
feasible. The allocation is blinded for the statistician conducting the 
data analysis. Additionally, we will write an abstract of study results 
prior to becoming aware of the group allocation and will include this 
abstract in the appendix of the original publication. Use of rand-
omization blocks of varying size not known for clinicians prevents 
knowledge of treatment allocation before randomization.
2.6 | Inclusion and exclusion criteria
All admissions to ICU will be screened. If the initial (static) inclusion 
or exclusion criteria (marked with asterisk) are not excluding the pa-
tient becoming eligible for randomization if oliguria develops, the 
patient will be followed further. If oliguria develops, the presence 
of dynamic exclusions will be rechecked, and if none of those is pre-
sent, patient is eligible for randomization.
2.6.1 | Inclusion criteria
• Age over 18*
• Emergency admission to an ICU*
• Mean arterial pressure (MAP) >65 mm Hg (with vasopressors if 
needed) and initial fluid resuscitation for shock/hypovolemia has 
been given
• Oliguria (urine output less than 0.5 mL/kg/h) for at least two con-
secutive hours
2.6.2 | Exclusion criteria
• Marked fluctuations in hemodynamics within the last 2 hours (car-
diac arrhythmias, increase in norepinephrine dose over 0.2 µg/
kg/min, initiation of inotrope/inodilator)
• Administration of furosemide within last 6 hours
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• Chronic kidney disease (estimated pre-critical illness GFR < 60 mL/
min/1.73 m2)*
• Renal replacement therapy*
• Urgent indications for commencing renal replacement therapy for 
AKI
• Fluid overload (cumulative fluid accumulation exceeds 10% of 
baseline body weight)13
• Pulmonary edema (bilateral infiltrates in chest x-ray)
• Active bleeding (need for transfusion, platelets, or fresh frozen 
plasma)
• Suspected or known intra-abdominal hypertension 
(IAP > 16 mm Hg)
• Pregnant or lactating*
• Expected survival less than 24 hours
• Obtaining informed written consent is not possible/ consent is 
denied
The detailed definitions of inclusion and exclusion criteria are 
presented in the Supplement.
2.7 | Trial interventions
The timeline of eligibility, randomization, and study interventions are 
presented in Table 1. The intervention period lasts 2 hours.
2.7.1 | Intervention group (noninterventional follow-
up)
Patients in the intervention group will not receive fluid bolus or diu-
retics to increase urine output during the 2-hour intervention period.
2.7.2 | Standard group (fluid bolus group)
Patients will receive 500 mL intravenous crystalloid (Ringer's ace-
tate) infused over 30 minutes using an infusion pump.
2.7.3 | Concomitant treatment
In both groups, the infusion rate of all on-going infusions such as 
nutrition and maintenance fluids will be kept constant during the 
2-hour period. Vasoactive drugs, short-acting insulin, sedation, and 
other medications can be titrated according to the discretion of the 
clinician. No diuretics during the 2-hour study period are allowed. 
Modifying the targeted mean arterial pressure (MAP) and adjusting 
vasopressor dose accordingly (higher MAP potentially increasing 
urine output19) are not recommended in either of the groups.
If severe hemodynamic instability develops during the 2-hour 
study period due to suspected hypovolemia (defined as a need to 
increase norepinephrine-infusion >0.2 µg/kg/min from baseline or 
heart rate increase >30 beats/min from baseline), a rescue bolus of 
500 mL crystalloid over 30 minutes in both groups can be adminis-
tered according to the decision of the treating clinician.
2.8 | Outcome measures
2.8.1 | Primary outcome measure
The primary outcome is defined the individual mean cumulative 
2-hour urine output (mL/kg/h) 2 hours after randomization di-
vided by the mean cumulative 2-hour urine output (mL/kg/h) 
measured 2 hours preceding randomization expressed as a per-
centage (Figure 1). Based on a previous prospective cohort study, 
we consider doubling of the urine output as a clinically significant 
increase in urine output among oliguric patients,20 if urine out-
put increases at least 10 mL/h (ie difference between cumulative 
2-hour urine output post-randomization vs pre-randomization is at 
least 20 mL).21 The proportion of patients who doubled their urine 
output in both groups will be compared.
Choosing the 2-hour timeline for the endpoint was based on as-
sumption that urine output in response to fluid bolus would increase 
in that time based on previous studies.22-24 In studies among healthy 
volunteers, the median/mean time to micturition after a large crys-
talloid bolus (saline 1 liter of over 30 minutes or 30 mL/kg adminis-
tered 100 mL/min) has been 82-112 minutes.22,23 Moreover, 2-hour 
cumulative urine output in response to Furosemide stress test per-
formed best in predicting worsening of AKI.24
2.8.2 | Secondary outcome measures
a.   The difference between groups in the change in individual urine 
output (with 95% CIs) at 2 hours
b. Duration of consecutive oliguria (urine output <0.5 mL/kg)
• Hours from randomization, assessed until resolved for the 
first time/patients is discharged/RRT is commenced)
c. Cumulative fluid balance on study day
• 6 hours from randomization
2.9 | Exploratory outcomes
a. Physiological effects from randomization until measured at 2 hours
(i) Mean arterial pressure
(ii) Heart rate
(iii) Norepinephrine dose
(iv) Central venous pressure (among those with central line)
(v) Difference in core vs peripheral temperature
(vi) Capillary refill time (until 60 minutes)
(vii) Blood pH
(viii) Standard base excess
(ix) Arterial lactate
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b. Number of patients receiving rescue boluses and the number of 
rescue boluses
• From randomization to 2 hours post-randomization
c. Number of patients with one or several protocol violation(s) and 
the number of those per patient
• From randomization to 2 hours post-randomization
Protocol violations include the following:
(i) Patient received Furosemide or other diuretic during the 2-hour 
period
TA B L E  1   Overview of the schedule of enrollment, interventions, and assessments according to the SPIRIT 2013 statement
Abbreviations: AKI, acute kidney injury; CRT, capillary refill time; RRT, renal replacement therapy.
Enrollment Allocation Post-allocation (hours from randomization)
TIMEPOINT ICU admission 
Presence of 
oliguria at 
least 2 
consecutive 
hours
Time of 
randomization 0-1 1-2 2-6
ICU 
discha
rge
Hospital 
discharge/
day 30
ENROLLMENT:
Initial eligibility screen X
Full eligibility screen
X
Informed consent 
Allocation X
INTERVENTIONS:
[Non-interventional 
follow-up]
[Fluid bolus 500mL 
crystalloid/30 minutes ] X
ASSESSMENTS:
[Baseline 
characteristics, 
chronic comorbidities, 
admission diagnosis, 
severity scores, organ 
support]
X X X
[Presense of 
stratification variables: 
sepsis and AKI ]
X
[Urine output]
[Hemodynamics, fluid 
therapy, peripheral 
temperature, CRT]
[Need for rescue bolus]
X X
[Presence of AKI and 
need for RRT]
[Mortality]
X
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(ii) Changing MAP target (defined as MAP level increased from base-
line target AND increased vasopressor dose from the baseline)
(iii) No full 500 mL bolus in bolus group
(iv) Fluid bolus (other than rescue bolus) in the follow-up group
(v) Erroneously randomized non-eligible patient
d. Number of patients with adverse events
• Assessed from randomization until the next morning
• Defined as events reported by the treating clinician in the 
open questionnaire included in the protocol
e. Highest AKI stage within
(i) 24 hours
(ii) 48 hours
(iii) During ICU stay
f. Number of patients receiving renal replacement therapy (during 
ICU stay)
2.10 | Data collection
Trained research personnel will perform data collection using an 
electronic platform (Absolute Imaginary Software Ltd). Data S1 
comprises the detailed list of collected data items. In brief, patient 
characteristics at baseline will be collected, and details of urine 
output, hemodynamics, and fluid therapy will be recorded during 
the intervention and follow-up period. Patients’ vital status will be 
recorded at hospital discharge or on day 30 whichever comes first.
2.11 | Statistical analysis
2.11.1 | General analytical principles
Statistical analyses will be performed on the intention-to-treat (ITT) 
population defined as all randomized subject excluding (a) those 
without consent (b) ineligible subjects who were erroneously rand-
omized and did not receive the trial intervention. The conclusions of 
the analysis will be based on the ITT analysis.
A sensitivity analysis will be conducted in the per-protocol population, 
defined as the ITT population and excluding subjects (a) who experienced 
one or several protocol violations or (b) who received the rescue bolus.
Continuous variables will be checked for normality using the 
Shapiro-Wilk test. We will set statistical significance to .05 and re-
port two-sided P-values.
2.11.2 | Primary outcome
The primary outcome between follow-up and fluid bolus groups 
will be adjusted for the two stratification variables25 (presence of 
AKI and presence of sepsis) using two-tailed logistic regression. 
Obtained odds ratios (OR) will be converted to risk ratios (RR) with 
95% confidence intervals (CI). Additionally, we will report crude 
event rates and risk ratios.
2.11.3 | Secondary and exploratory outcomes
As the primary outcome, the secondary and exploratory outcomes 
will be adjusted for the two stratification variables.25 Continuous 
measures will be expressed according to their distribution and dif-
ference between the groups in the change in individual urine out-
put, duration of consecutive oliguria, and cumulative fluid balance 
on study day will be compared using mean or median regression 
depending on normal distribution and expressed with 95% CIs. 
Dichotomous endpoint measures (number of patients receiving res-
cue boluses, highest AKI stage within 24, 48 hours and during ICU 
stay, and number of patients receiving RRT) will be analyzed using 
ordinal or logistic regression and reported as risk ratios with 95% CIs. 
Furthermore, crude event rates and risk rations will be reported for 
dichotomous outcomes and absolute differences with 95% CIs for 
continuous outcomes.
2.11.4 | Other variables
Continuous variables will be compared with Mann-Whitney U test 
or Student's t test depending on normal distribution, and categorical 
data using Chi-squared test.
2.11.5 | Missing data
We do not expect to have missing data about the primary out-
come measure or stratification variables in the ITT population. 
Regarding secondary or exploratory outcomes, some missingness 
F I G U R E  1   Schematic presentation of determination of urine 
output for the primary endpoint variable. UO, urine output
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is expected (for example CVP values in patients who have not a 
central line inserted), but imputation will not be used. Regarding 
other data points, if the amount of missing observations regarding 
other variables is less than 5%, we do not impute data. Regarding 
descriptive data, an appropriate multiple imputation strategy ac-
cording to the type of missingness (missing at random or missing 
completely at random) will be used if missingness exceeds 5% of 
observations.
2.12 | Sample size
No reliable previous data to inform about the incidence of the pri-
mary outcome were available. Among oliguric (urine output <0.5 mL/
kg/h for at least 3 hours), hemodynamically stable patients, 50% were 
considered as renal responders to a fluid challenge that constituted at 
least one 500 mL crystalloid bolus administered over 15 minutes.10 In 
that study the definition of a positive renal response (post-bolus urine 
output over 0.5 mL/kg/h for at least 3 hours) was more liberal than in 
our trial.10 Fluid bolus did not significantly increase urine output among 
patients with acute respiratory distress syndrome (both oliguric and 
non-oliguric).5 Therefore, we assume that 30% of patients in the fluid 
bolus group will be endpoint-positive. Additionally, we consider 20% 
absolute difference (which translates to a number needed to treat of 5) 
as a minimum clinically meaningful difference between the groups to 
support the use of such a common and inexpensive intervention. Thus, 
to reach a 20% absolute difference in the primary outcome (30% in the 
fluid bolus group and 10% in the noninterventional follow-up group), 
62 patients per group will be required to reach 80% power with signifi-
cance level set at .05 (two-sided). Considering possible drop-outs we 
aim to randomize 65 patients per group to target at least 62 patients 
per group in the ITT population.
2.13 | Pre-planned subgroup analyses
The primary and secondary outcome measures will be analyzed in 
two pre-defined subgroups: (a) patients with sepsis according to sep-
sis-3 definition18 and (b) patients with AKI defined by the KDIGO 
criteria.4 Presumably, patients with AKI may exert a poorer response 
in terms of urine output to fluid bolus than those without AKI. 
Additionally, the recent pathophysiological hypotheses regarding 
oliguria in sepsis suggest that oliguria may be an adaptive mecha-
nism to severe inflammation,26 suggesting also a lower incidence of 
reversal of oliguria. The results obtained in the subgroups will be 
interpreted as hypothesis generating and heterogeneity between 
subgroups will be assessed by I2-test.
2.14 | Trial Profile
The flow of trial participants will be reported according to the 
CONSORT statement.27
2.15 | Data monitoring and safety committee
As this is a low-risk pilot trial, no data and safety monitoring commit-
tee (DSMB) will be formed. Informed consents, inclusion and exclu-
sion criteria, and collected data will be monitored.
2.16 | Interim analyses
No interim analyses will be conducted.
3  | DISCUSSION
Albeit fluid bolus therapy is frequently used in oliguria to increase 
urine output, the success of this intervention is largely unknown. 
The RESPONSE trial will give high-quality information about the 
physiological outcomes of fluid bolus therapy given for oligu-
ria in hemodynamically stable patients compared to a follow-up 
treatment strategy without additional fluids. Conservative fluid 
resuscitation strategies especially in septic patients are actively in-
vestigated28,29 as the evidence regarding harms of fluid overload 
are being increasingly recognized, especially among patients with 
AKI.30,31 The results of RESPONSE trial will help to assess the po-
tential benefit of fluid bolus therapy, and if no clinically meaningful 
improvement on urine output or other physiological variables can 
be demonstrated, will help in avoiding unnecessary fluid loading in 
the future.
The randomized approach in studying the response of fluid bolus 
therapy to an alternative intervention is an obvious strength of 
our study, as the current evidence is based on observational data. 
Moreover, we are carefully recording data on other fluid input and 
output, common hemodynamic parameters, acid-base balance, and 
blood gases. Thus, we will be able to provide a detailed analysis on 
the effects of fluid bolus on these parameters as compared to the 
follow-up approach. Additionally, we will include a heterogeneous 
population of critically ill patients with oliguria who have received 
the initial fluid resuscitation, which will improve the generalizability 
of our results.
Our trial has some obvious limitations. First, the intervention 
is not blinded from the clinical team or the investigators due to its 
nature. Potentially, clinician aware of the patient being in the fol-
low-up group may give a fluid bolus after the intervention period, 
and therefore neutralizing the difference between the groups re-
garding fluid balance. However, we record the details of urine out-
put and fluid therapy until 6 hours post-randomization to assess 
the administration additional fluid boluses. Moreover, the trial 
statistician will be blinded to the group allocation. Second, our 
trial protocol does not mandate cardiac output monitoring, and 
therefore, commenting whether patients were hemodynamic fluid 
responders will not be possible. However, numerous studies have 
shown that global hemodynamics and renal hemodynamics do not 
correlate.7,10
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In conclusion, the RESPONSE trial will bring new evidence about 
the effects of fluid bolus therapy compared to noninterventional fol-
low-up on urine output. These results will help to allocate fluid bolus 
therapy to those patients who benefit from it.
4  | ETHIC AL CONSIDER ATIONS AND 
CONSENT TO PARTICIPATE
The Ethics Committee of Department of Surgery, Hospital district 
of Helsinki and Uusimaa (HUS/1308/2016), approved the trial. 
Because of the critically ill patient population and a time-sensitive 
standard group intervention, deferred consent was approved with 
an informed, written consent obtained from the patients’ next of 
kin as soon as possible and confirmed from the patient if possible. 
Patient will be asked to provide the consent prior to randomization if 
his/her clinical situation allows. Written informed consent is manda-
tory for all patients included in the final analysis.
5  | DATA SHARING STATEMENT
The de-identified trial data set will be published as a supplement to 
the original publication.
6  | DISSEMINATION
Results of the study will be submitted to a peer-reviewed medical 
journal regardless of the results.
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